Biomarkers for benign prostatic hyperplasia progression

Oesterling JE: Benign prostatic hyperplasia: a review of its histogenesis and natural history. Prostate Suppl 1996, 6:67–73.

Wei JT, Calhoun E, Jacobsen SJ: Urologic Diseases in American Project: benign prostatic hyperplasia. J Urol 2005, 173:1256–1261.

Rosen R, Altwein J, Boyle P, et al.: Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003, 44:637–649.

Rames RA, Horger DC: α-Adrenergic antagonists in the treatment of benign prostatic hypertrophy-associated lower urinary tract symptoms. In Management of Benign Prostatic Hypertrophy. Edited by McVary K. Totowa, NJ: Humana Press; 2004:61–77.

McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398.

Fenter TC, Naslund MJ, Shah MB, et al.: The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care 2006, 12:S90–S98.

Hollingsworth JM, Wei JT: Economic impact of surgical intervention in the treatment of benign prostatic hyperplasia. Rev Urol 2006, 8(Suppl 3):S9–S15.

Yang Q, Fung KM, Day WV, et al.: Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 2005, 5:8.

Berthon P, Waller AS, Villette JM, et al.: Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. Int J Cancer 1997, 73:910–916.

Bartsch G, Rittmaster RS, Klocker H: Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002, 19:413–425.

Schwinn DA, Michelotti GA: Alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int 2000, 85(Suppl 2):6–11.

Untergasser G, Madersbacher S, Berger P: Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005, 40:121–128.

Prakash K, Pirozzi G, Elashoff M, et al.: Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A 2002, 99:7598–7603.

Cannon G, Mullins C, Lucia M, et al.: A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. J Urol 2007, 177:610–614.

Oztekin CV, Ozturk B, Tas M, et al.: How do patients with familial benign prostatic hyperplasia differ clinically from those with sporadic benign prostatic hyperplasia? Urol Int 2006, 76:332–334.

Sanda MG, Beaty TH, Stutzman RE, et al.: Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994, 152:115–119.

Sanda MG, Doehring CB, Binkowitz B, et al.: Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 1997, 157:876–879.

Pearson JD, Lei HH, Beaty TH, et al.: Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 2003, 61:781–785.

Rhodes T, Girman CJ, Jacobsen SJ, et al.: Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999, 161:1174–1179.

Marks LS, Roehrborn CG, Andriole GL: Prevention of benign prostatic hyperplasia disease. J Urol 2006, 176:1299–1306.

Roehrborn CG, Boyle P, Gould AL, et al.: Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999, 53:581–589.

Bartsch G, Fitzpatrick JM, Schalken JA, et al.: Consensus statement: the role of prostate-specific antigenin managing the patient with benign prostatic hyperplasia. BJU Int 2004, 93(Suppl 1):27–29.

Froehner M, Hakenberg OW, Koch R, et al.: Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer. Urol Int 2006, 76:27–30.

Jung K, Elgeti U, Lein M, et al.: Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000, 46:55–62.

Mikolajczyk SD, Millar LS, Wang TJ, et al.: “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 2000, 55:41–45.

Mikolajczyk SD, Marks LS, Partin AW, et al.: Free prostate-specific antigen in serum is becoming more complex. Urology 2002, 59:797–802.

Wang TJ, Slawin KM, Rittenhouse HG, et al.: Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. Eur J Biochem 2000, 267:4040–4045.

Linton HJ, Marks LS, Millar LS, et al.: Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 2003, 49:253–259.

Bull JH, Ellison G, Patel A, et al.: Identification of potential diagnostic markers of prostate cancer and prostatic intraepithelial neoplasia using cDNA microarray. Br J Cancer 2001, 84:1512–1519.

Wright GL Jr, Beckett ML, Newhall KR, et al.: Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia. Prostate 2000, 42:230–238.

Madersbacher S, Pycha A, Klingler CH, et al.: The International Prostate Symptom score in both sexes: a urodynamics-based comparison. Neurourol Urodyn 1999, 18:173–182.

Boyle P, Robertson C, Mazzetta C, et al.: The prevalence of lower urinary tract symptoms in men and women in four centres: the UrEpik study. BJU Int 2003, 92:409–414.